BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 6, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Toleranzia files European CTA to begin first-in-human study of TOL-2
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Toleranzia files European CTA to begin first-in-human study of TOL-2
Oct. 3, 2024
No Comments
Toleranzia AB has filed a clinical trial application (CTA) with the EMA for a phase I/IIa trial of TOL-2 in patients with myasthenia gravis.
BioWorld Science
Regulatory
Immune
EMA
